Skip to main content

Table 1 Table

From: Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven®) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial

 

Placebo

rFVIIa

P

Failure on composite endpoint

   

All patients

19/123

16/122

0.72

   Variceal bleeders

16/82

8/79

0.12

   Variceal bleeders Child B–C

15/65

5/63

0.03

Failure to control acute bleeding (within 24 hours)

   

   Variceal bleeders

8/82

2/79

0.10

   Variceal bleeders Child B–C

7/65

3/63

0.01

Failure to prevent rebleeding (24 hours-day 5)

   

   Variceal bleeders

9/82

5/79

0.40

   Variceal bleeders Child B–C

8/65

3/63

0.13

Failure to control acute bleeding or failure to prevent rebleeding within 5 days

   

   Variceal bleeders

13/82

6/79

0.14

   Variceal bleeders Child B–C

12/65

3/63

0.03

  1. Values are shown as failures/number of patients.
Back to article page

Critical Care

ISSN: 1364-8535